Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruben Smith

Showing results (81-90 of 139) with videos related to

Pageof 14
Sort By:
JAMA Neurology|May 19, 2025
Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer DiseaseAlexa Pichet Binette, Ruben Smith, Gemma Salvadó, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
Medial temporal lobe atrophy patterns in early- versus late-onset amnestic Alzheimer's diseaseAnika Wuestefeld, Alexa Pichet Binette, Danielle van Westen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 13, 2022
[<sup>18</sup>F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromesAlexander F Santillo, Antoine Leuzy, Michael Honer, et al.
Nature Medicine|March 4, 2020
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementiaShorena Janelidze, Niklas Mattsson, Sebastian Palmqvist, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersAlexa Pichet Binette, Ruben Smith, Gemma Salvadó, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 27, 2021
A multicenter comparison of [<sup>18</sup>F]flortaucipir, [<sup>18</sup>F]RO948, and [<sup>18</sup>F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosisAntoine Leuzy, Tharick A Pascoal, Olof Strandberg, et al.
JAMA Neurology|December 4, 2023
Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid ImmunotherapiesNiklas Mattsson-Carlgren, Lyduine E Collij, Erik Stomrud, et al.
Science Advances|May 20, 2020
Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's diseaseNiklas Mattsson-Carlgren, Emelie Andersson, Shorena Janelidze, et al.
JAMA|July 28, 2024
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary CareSebastian Palmqvist, Pontus Tideman, Niklas Mattsson-Carlgren, et al.
JAMA Neurology|December 20, 2021
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer DiseaseAntoine Leuzy, Ruben Smith, Nicholas C Cullen, et al.
Pageof 14

Showing results (81-90 of 139) with videos related to

Sort By:
Pageof 14
JAMA Neurology|May 19, 2025
Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer DiseaseAlexa Pichet Binette, Ruben Smith, Gemma Salvadó, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
Medial temporal lobe atrophy patterns in early- versus late-onset amnestic Alzheimer's diseaseAnika Wuestefeld, Alexa Pichet Binette, Danielle van Westen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 13, 2022
[<sup>18</sup>F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromesAlexander F Santillo, Antoine Leuzy, Michael Honer, et al.
Nature Medicine|March 4, 2020
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementiaShorena Janelidze, Niklas Mattsson, Sebastian Palmqvist, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersAlexa Pichet Binette, Ruben Smith, Gemma Salvadó, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 27, 2021
A multicenter comparison of [<sup>18</sup>F]flortaucipir, [<sup>18</sup>F]RO948, and [<sup>18</sup>F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosisAntoine Leuzy, Tharick A Pascoal, Olof Strandberg, et al.
JAMA Neurology|December 4, 2023
Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid ImmunotherapiesNiklas Mattsson-Carlgren, Lyduine E Collij, Erik Stomrud, et al.
Science Advances|May 20, 2020
Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's diseaseNiklas Mattsson-Carlgren, Emelie Andersson, Shorena Janelidze, et al.
JAMA|July 28, 2024
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary CareSebastian Palmqvist, Pontus Tideman, Niklas Mattsson-Carlgren, et al.
JAMA Neurology|December 20, 2021
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer DiseaseAntoine Leuzy, Ruben Smith, Nicholas C Cullen, et al.
Pageof 14